Lactoferrin prevents biofilm formation at wound

描述（由申请人提供）：伤口愈合是老年人的主要健康问题。生物膜在伤口部位的发育使得许多现有的治疗方法对伤口病原体无效，因为当细菌受到生物膜的保护时，它会增加对抗生素的耐药性。被生物膜保护的细菌对抗生素的耐药性增加了100到1000倍。最近的研究表明，人乳铁蛋白对防止生物膜的形成是有效的。在稻谷中生产重组人乳铁蛋白（rhLF）为以可承受的成本生产大量原料奠定了基础。提出了一种基于rhlf的治疗方法来促进伤口愈合。在第一阶段，将扩大米粒的规模，并开发一种从米粒中高效纯化乳铁蛋白的工艺。该程序将用于制备高质量的rhLF，然后用于测试rhLF对从伤口部位分离的各种细菌菌株（包括抗生素耐药菌株）生物膜形成的影响。

DESCRIPTION (provided by applicant): Wound healing is a major health issue for the elderly. Biofilm development at the wound site renders many existing treatments ineffective in treating wound pathogens because when bacteria is protected by biofilm it increases its resistance to antibiotics. Bacteria protected by biofilm demonstrate a 100 to 1000 fold increase in resistance to antibiotics. Recent research has shown that human lactoferrin is effective in preventing biofilm formation. Production of recombinant human lactoferrin (rhLF) in rice grain provides the foundation for large quantities of raw material at an affordable cost. A rhLF-based treatment to enhance wound healing is proposed. In phase I, rice grain will be scaled up and a process to efficiently purify lactoferrin from rice grain will be developed. This procedure will be used to prepare quality rhLF, which would then be used to test rhLF's effect on biofilm formation for various bacterial strains isolated from wound site including antibiotic resistant strains.